Dassault Systèmes has partnered with Swiss biotherapeutics firm CDR-Life to expedite the development of the latter’s next-generation highly tumour-selective immunotherapies.

Both firms will work on the scientific innovation for cancer therapies using CDR-Life’s proprietary M-gager platform.

Under the partnership, Dassault Systèmes, a science-based firm with virtual twin experiences, and CDR-Life will study the stability of antibody-based biologics known as T-cell engagers.

The scientists from the contract research team at Dassault Systèmes collaborated with researchers from CDR-Life to conduct virtual “what if” tests on these T-cell engagers.

The joint research team will use Dassault Systèmes’ BIOVIA software and CDR-Life’s experimental data.

Additionally, the team at Dassault Systèmes used their scientific and technological expertise to virtually model different molecules and find those that will have desirable features like stability without affecting other chemical functions.

The team submitted the variants that were expected to have a high probability of success when tested in the lab by CDR-Life after conducting a comprehensive and methodical study of the data.

CDR-Life discovery leader Fabian Scheifele said: “Our collaboration with Dassault Systèmes’ Contract Research team accelerated our research and development efforts based on our proprietary antibody-based MHC-targeting T-cell engager technology.

“By working together, we can use the insights gathered virtually for our protein engineering platform and pave the way toward more efficient and effective oncology treatments.”

Dassault Systèmes said that next-generation immunotherapies help the immune system to destroy cancerous cells with unmatched specificity and support effective cancer treatment.

With the help of its contract research team, Dassault Systèmes helps both new and current clients across all industries with their business-critical scientific problems.

Dassault Systèmes life sciences and healthcare industry vice president Claire Biot said: “Pharmaceutical and biotechnology companies of all sizes seek to accelerate the development of therapies that will help people live healthier lives.

“Our outcome-based Contract Research service is a game-changer in how we work with our customers on projects. CDR-Life was able to focus its time and energy on prioritized experiments with the most promising candidates.”